The number of shareholders has changed from 19 to 24 in the event of an equity change in Kaiser Bio.

According to the IPO early know, the biomanufacturing industry pioneer ——— recently in the coaching period occurred in the equity changes, the number of shareholders from the original 19 to 24.
According to the information disclosed by CITIC Securities, the five new shareholders are Shenzhen Zhaoyin Langyi Growth Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as "China Merchants Langyi"), Shenzhen Merchant Bank No. 1 Innovation Venture Investment Partnership (Limited Partnership) (hereafter referred to as "China Merchants Bank One" Shenzhen Bid Bank Win-Win Equity Investment Partnership (Limited Partnership) (hereafter referred to as "China Merchants Win-Win"), Hangzhou Yantian Investment Partnership (Limited Partnership) (hereafter "Hangzhou Yantian"), Wuxi Changgu Investment Partnership (Limited Partnership) (hereafter referred to as "Wuxi Changgu").
it is understood that after the completion of the external capital increase, the total number of shares in Kaisai Bio increased from 357 million shares to 375 million shares.
Day Eye survey data show that the new shareholders of the bank, Bank of China No. 1, China Merchants Win-win its actual control of the bank's international capital Limited (hereafter referred to as "China Merchants International");
IPO had been informed through inquiries that Xu had previously served as managing director of Citic Mergers and Acquisitions Fund Management Co., Ltd.
it is worth noting that, through this capital increase to Kaiser Bio, the latter held 14.2862 million shares, the shareholding of 3.8%, into the top 10 list of Kaiser Bio's major shareholders.
public information shows that Kaisai Bio, formerly known as Shanghai Kaisai Biotechnology Research and Development Center Co., Ltd. (hereafter referred to as "Kaisai Biotechnology"), which was founded in November 2000, has a business scope including technical research, development, technology transfer, technical advice on bio-new materials monomers and polymers and polymers, biomedicine, food and feed additives, etc.
August 27, 2019, Kaiser Biotech completed the joint-stock transformation, officially renamed Kaisai Bio.
based on the IPO's previous reports on Kaiser Bio, the company received listing guidance from CITIC Securities on September 16 and conducted a pre-guidance filing with the Shanghai Securities Regulatory Commission on September 20, 2019.
currently, Liu Xiucai is the chairman and CEO of the company, and CATHAY INDUSTRIAL BIOTECH LIMITED (HEREafter referred to as "Kaiser Bio-Industries") is the actual controller by holding a 31.47 percent stake in Kaiser Bio.
IPOs have learned that Kaiser Bio currently has a research and development center and two production sites in China.
Kaisai Biologicals in Shandong Kaisai long-chain binary acid production base in 2002 has been industrialization, the current annual production capacity of 40,000 tons, is the world's largest supplier of the product.
the success of the project is also a commercial success story in the world for biolegal products to replace petrochemical products.
in recent years, Kesai Bio developed bio-based diamine and produced a range of bio-based polyamides with excellent performance, and successfully completed the industrialization test run in 2014.
notethat, the bio-based polyamide of Kesai bio-organisms comes from renewable biomass feedstocks.
this is a new "biomanufacturing" new material that has been introduced after the invention of nylon 66 and 6 years after the traditional chemical method, which can be widely used in textiles and engineering plastics.
this new biobiotic material after ten years of research and development and industrial production for textile and other fields, is the first time in the world.
as china's first industrialbio-based synthetic fiber, bio-based polyamide has become the country's "Belt and Road" signed a major project.
on the other hand, the first phase of construction of the Usu production base in Kaisai Bio-Xinjiang is expected to achieve an annual production capacity of 50,000 tons of bio-based diamide, an annual production capacity of 100,000 tons of bio-based polyamide and an annual production capacity of 30,000 tons of long-chain binary acid, is also in the trial production phase.
the first step of the IPO by the pioneers of the biomanufacturing industry: Kaisai Bio received listing counseling According to the IPO early knowledge of the news, the Shanghai Securities Regulatory Commission disclosed on September 24, Shanghai Kaisai Biotechnology Co., Ltd. (hereinafter referred to as "Kasai Bio") intends to initially issue shares and listed on the domestic exchange, has received CITIC Securities guidance, and on September 20, 2019 in Shanghai Securities Regulatory Commission conducted a counseling record.
Kaisai Bio, formerly known as Shanghai Kaisai Biotechnology Research and Development Center Co., Ltd. (hereafter referred to as "Kaisai Biotechnology"), has a business scope including bio-new material monomers and polymers and polymers, biomedicine, food and feed additives, etc.
August 27, 2019, Kaiser Biotech completed the joint-stock transformation, officially renamed Kaisai Bio.
currently, Liu Xiucai is the company's chairman and CEO.
SkyEye data shows that Kaiser Bio-Industries Limited (HEREinafter referred to as "Kaiser Bio-Industries") holds a 33.04% stake in Kaiser Bio, the actual controller.
IPO early to know that the reporter learned that Kaisai bio-industry was founded in 1997 by China University of Science and Technology 77 alumnus Dr. Liu Xiucai, since its inception, the company focused on bio-manufacturing industrialization technology development and practice, has achieved large-scale industrialization of projects including long-chain duotic acid, biobutanol, bio-based dilinemine, bio-based polyamide.
official website, Kaisai Bio currently has a research and development center and two production sites in China.
research and development center is located in The Zhangjiang High-Tech Park in Shanghai.
its industrial development platform covers molecular biology, fermentation process engineering, polymer materials and other professional fields of research.
Kaisai Biologicals in Shandong Kaisai long-chain binary acid production base in 2002 has been industrialization, the current annual production capacity of 40,000 tons, is the world's largest supplier of the product.
the success of the project is also a commercial success story in the world for biolegal products to replace petrochemical products.
in recent years, Kesai Bio developed bio-based diamine and produced a range of bio-based polyamides with excellent performance, and successfully completed the industrialization test run in 2014.
notethat, the bio-based polyamide of Kesai bio-organisms comes from renewable biomass feedstocks.
this is a new "biomanufacturing" new material that has been introduced after the invention of nylon 66 and 6 years after the traditional chemical method, which can be widely used in textiles and engineering plastics.
this new biobiotic material after ten years of research and development and industrial production for textile and other fields, is the first time in the world.
as china's first industrialbio-based synthetic fiber, bio-based polyamide has become the country's "Belt and Road" signed a major project.
on the other hand, the first phase of construction of the Usu production base in Kesai Bio-Xinjiang is expected to achieve an annual production capacity of 50,000 tons of bio-based diamide, an annual production capacity of 100,000 tons of bio-based polyamide and an annual production capacity of 30,000 tons of long-chain binary acid, which is currently in the trial production phase.
it is understood that its founder, Dr. Liu Xiucai, is well-known in the industry and has been focused on industry and keeping a low profile.
as an entrepreneur in the field of bio-industry, Liu Xiucai has been concerned about the scientific value and social significance of bionic materials.
In the context of increasingly tight oil resources and environmental pollution has become a global challenge, bio-based fibers from renewable biomass have become a new bright spot and growth point in the textile and chemical fiber industry.
China has listed bio-based fiber as the key task of the "13th Five-Year Plan" textile and chemical fiber industry development, bio-based materials are an important breakthrough in the strategy of fossil resource substitution, an important part of the country's strategic emerging industries, and an urgent need for the development of the national economy.
, Dr. Liu Xiucai said in public that the accelerated emissions of carbon dioxide due to the increasing demand for polymer icing materials have had a negative impact on the environment, while biomanufacturing can reduce pollution by changing the cycle of carbon dioxide.
Kasai Bio, as a pioneer in the biomanufacturing industry, has been working in the industry for more than 20 years, and this time accepting the listing guidance of CITIC Securities also bodes well for The first step in the IPO.
and for the future specific listing plate selection, IPO had known the reporter called The head of The Kesai Biological Lin surname, the other side did not disclose the relevant information and hung up the phone.
on this matter, the IPO had known that it would continue to pay attention.
Source: IPO